Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-12

Clinical Trial Update: Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding study of BI 655064 in patients with active lupus nephritis has been completed, with results on efficacy and safety reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 655064

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-12